

CONCISE REPORT

Rearrangement and Expression of T-Cell Receptor Genes in Large Granular Lymphocyte Leukemia

By Thomas P. Loughran, Jr, Gordon Starkebaum, and Joseph A. Aprile

Ten patients with large granular lymphocyte (LGL) leukemia were studied for rearrangement and expression of T cell receptor (TCR) genes. Eight patients with CD3+ LGL proliferation had unique TCR β -gene rearrangements, supporting a clonal process. Each of five patients studied with CD3+ disease had evidence for expression of full-length TCR α -, β -, and γ -gene transcripts. In contrast, patients with CD3- LGL proliferation had no evidence for rear-

range or expression of TCR genes. These studies suggest that leukemic LGL arise from two different cell origins. Leukemic LGL may be a useful model for studying natural killer (NK) cell (CD3- LGL) and non-MHC-restricted cytotoxic T lymphocyte (CD3+ LGL) activation and differentiation.

© 1988 by Grune & Stratton, Inc.

INITIAL PHENOTYPIC studies of large granular lymphocytes (LGL) concluded that the surface antigen phenotype of these cells was heterogeneous.¹ However, it is now clear that LGL can be divided into two discrete subsets: CD3- LGL and CD3+ LGL.² CD3- LGL, comprising approximately 10% of peripheral blood mononuclear cells (PBMC), do not rearrange T cell receptor (TCR) genes, supporting a non-T lineage for these cells.^{3,4} CD3+ LGL, constituting approximately 2% of PBMC, are of T lineage, since they rearrange TCR genes.⁵ Both LGL subsets mediate non-MHC-restricted cytotoxicity. Because of their phenotypic and molecular features, it has been proposed that these two subsets be recognized as discrete cell types: NK cells (CD3- LGL) and non-MHC-restricted cytotoxic T lymphocytes (CD3+ LGL).²

LGL leukemia results from a chronic proliferation of LGL that is associated with chronic neutropenia and rheumatoid arthritis.⁶ Leukemic LGL may be either CD3- or CD3+, suggesting that neoplastic cells may represent proliferation of either of the two normal cell types. In this study we examined rearrangement and expression of TCR genes in cells from patients with LGL leukemia. Our results show that leukemic LGL have molecular features similar to their CD3- and CD3+ normal counterparts.

MATERIALS AND METHODS

Patients. All patients met clinical criteria for diagnosis of LGL leukemia.⁷ LGL counts varied from 3,300 to 20,000/ μ L (normal: 223 \pm 99 cells/ μ L, n = 10). Previous publications have detailed the

clinical course of patients 1, 2, 5, and 8,^{6,8} lymphocyte surface markers for patients 1 through 5 and 7,⁹ and TCR β -gene rearrangement studies for patients 1, 2, and 8.⁸ Patients 1 through 8 had CD3+ LGL disorder (reactivity of PBMC with anti-CD3 monoclonal antibody [MoAb] ranging from 78% to 99%), whereas patients 9 and 10 had CD3- disease (27% and 16% of PBMC reacting with anti-CD3 MoAb, respectively).

Blot hybridization analyses. Genomic DNA was extracted from PBMC as described⁸ and was digested with restriction enzymes *Bam*HI, *Eco*RI, or *Hind*III. Digested DNA was separated on 1.1% agarose gels and transferred onto nitrocellulose filter by method of Southern.¹⁰ RNA was extracted from PBMC in the presence of guanidine thiocyanate, size fractionated by agarose/formaldehyde gel electrophoresis, and transferred onto nitrocellulose filter.¹¹ Filters were then hybridized to DNA probes ³²P-labeled by nick translation and visualized by autoradiography.⁸

The cDNA clones for TCR α , β , and γ genes were kindly provided by Dr Tak Mak (Ontario Cancer Institute, Toronto, Canada). Clone pY14 contains a full length copy of TCR α gene cDNA,¹² clone Jurkat β_2 contains the constant and joining regions of TCR β gene,¹³ and the clone for TCR γ gene contains a full length copy of TCR γ gene cDNA.¹⁴ The β -actin cDNA probe¹⁵ was kindly provided by Dr Steven Collins (Fred Hutchinson Cancer Research Center, Seattle, WA).

RESULTS

Results of Southern blot hybridization analyses using TCR β gene probe are shown in Fig 1. Analysis of DNA after digestion with *Bam*HI or *Hind*III showed unique rearrangements of TCR β gene in each of eight patients with CD3+ disease. In contrast, germ-line pattern was observed in patients 9 and 10 with CD3- LGL leukemia using both these enzymes (Fig 1) as well as *Eco*RI (not shown). The rearrangement pattern for patient 1 after *Bam*HI analysis differs somewhat from that previously published⁸ in that an additional faint band at 6 kilobase (kb) was noted. This finding has been confirmed in two subsequent experiments. TCR α -gene rearrangement was noted in one patient (CD3+ LGL leukemia); another patient (also with CD3+ disease) had rearrangement of TCR γ gene (not shown). The inability to detect TCR α - and γ -gene rearrangement in the other CD3+ patients may result from such rearrangements using different joining regions occurring over large distances of DNA.^{16,17} Detection of these rearrangements might require use of multiple joining region probes and/or pulsed-field-gradient-gel electrophoresis.^{16,17} Alternatively, one can examine for TCR messenger RNA (mRNA; see below), since expression of full-length TCR gene transcripts is evidence of prior rearrangement of TCR genes.

From the Fred Hutchinson Cancer Research Center, the Division of Rheumatology, Department of Medicine, University of Washington School of Medicine; and the Veterans Administration Medical Center, Seattle.

Submitted October 28, 1987; accepted November 21, 1987.


Supported by PHS Grant Nos. CA 18821, BRSG RR 05761-12, and HL 36444 awarded by the National Institutes of Health, DHHS and by the Leukemia Research Foundation. Dr Thomas P. Loughran is a Special Fellow of the Leukemia Society of America.

Address reprint request to Thomas P. Loughran, Jr, MD, Fred Hutchinson Cancer Research Center, 1124 Columbia St, Seattle, WA 98104.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1988 by Grune & Stratton, Inc.
0006-4971/88/7103-0039\$3.00/0

Fig 1. Results of Southern blot hybridization analyses using TCR β -gene probe showing rearrangement patterns after digestion with *Bam*HI or *Hind*III. Lanes 1 through 8 represent CD3+ LGL leukemia patients, lanes 9 and 10 CD3- LGL leukemia patients, and lane 11 the germ-line pattern obtained when analyzing DNA extracted from neutrophils of a normal volunteer. Arrowheads indicate position of rearranged bands. The gels are not aligned because the studies were carried out at different times. Sizes of rearranged fragments are as follows. For *Bam*HI: patient 1, 16 kb and 6 kb; patient 2, 16 kb; patient 3, 11 kb; patient 4, 16 kb and 9 kb; patient 5, 12 kb; patient 6, 8 kb; patient 7, 25 kb; and for patient 8, 20 kb. For *Hind*III analysis: patient 1, 22 kb; patient 2, 14 kb; patient 3, 14 kb; and for patient 4, 23 kb, 9 kb, and 6.8 kb.



Results of Northern blot hybridization analyses using TCR α -, β -, and γ -gene probes are shown in Fig 2. Expression of full-length transcripts for TCR α -, β -, and γ -genes was seen in three patients with CD3+ LGL leukemia (similar results were observed in the other two patients examined with CD3+ disease, not shown). Two of five CD3+ LGL leukemia patients also expressed a 1.0-kb TCR β -gene transcript. In contrast, in the one CD3- patient examined, there was no expression of TCR α -, β -, or γ -gene transcripts. This was not due to a lack of RNA loaded in the gel, as shown by hybridization to β -actin probe.




Fig 2. Results of Northern blot hybridization analyses using TCR gene probes and β -actin gene probe. Lanes 1 through 3 represent CD3+ patients (lane 1, patient 6; lane 2, patient 2; and lane 3, patient 5). Lane 4 represents patient 10 with CD3- LGL leukemia, and lane 5 represents RNA extracted from tumor cell line HPB-ALL, used as control.

DISCUSSION

These results show that CD3- and CD3+ leukemic LGL have molecular characteristics that suggest different cell origins. Previous TCR β -gene rearrangement studies have shown germ-line configuration of TCR β gene in all five patients studied with CD3- LGL leukemia,¹⁸⁻²⁰ whereas 19 of 23 patients with CD3+ disease had TCR β -gene rearrangement.¹⁸⁻²² Our studies confirm and extend those findings by demonstrating germ-line configuration of TCR α , β , and γ genes in two patients and absence of expression of these gene transcripts in one patient examined with CD3- LGL leukemia. These results are similar to those seen in normal CD3- LGL (NK cells), supporting a non-T lineage for these cells.³⁻⁵

In contrast, we found expression of TCR α -, β -, and γ -gene transcripts in cells from patients with CD3+ LGL leukemia. Similar findings of expression of TCR α -, β -, and γ -gene transcripts have been noted in cloned murine Thy-1+ LGL cell lines.²³ We had previously shown that these CD3+ leukemic LGL may exhibit non-MHC-restricted cytotoxicity.⁹ Some recent evidence suggests that TCR γ -protein may serve as a functional receptor involved in non-MHC-restricted lysis.²⁴ The precise role of expression of TCR γ -gene transcripts in CD3+ leukemic LGL awaits further study.

Rearrangement of TCR β gene could be used as evidence for clonality or, alternatively, might reflect a stage of normal LGL differentiation. For example, one similar TCR β -gene rearrangement has been observed in murine LGL cell lines,²³ suggesting that the similar rearrangement might be associated with a differentiation stage. In contrast, our finding of unique TCR β -gene rearrangements in each of eight patients with CD3+ LGL leukemia supports the clonal nature of this disorder.⁶ Our studies support a non-T cell origin for CD3- leukemic LGL and a T cell origin for the CD3+ leukemic LGL. Therefore leukemic LGL may be useful for studying activation of two different classes of cytotoxic lymphocytes: NK cells and non-MHC-restricted cytotoxic T lymphocytes.

NOTE ADDED IN PROOF

Similar molecular findings for CD3- and CD3+ leukemic LGL have been described by Pelicci et al.²⁵

REFERENCES

1. Ortaldo JR, Sharrow SO, Timonen T, Herberman RB: Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. *J Immunol* 127:2401, 1981
2. Lanier LL, Phillips JH, Hackett J Jr, Tutt M, Kumar V: Natural killer cells: Definition of a cell type rather than a function. *J Immunol* 137:2735, 1986
3. Lanier LL, Cwirla S, Federspiel N, Phillips JH: Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor β chain genes. *J Exp Med* 163:209, 1986
4. Lanier LL, Cwirla S, Phillips JH: Genomic organization of T cell γ genes in human peripheral blood natural killer cells. *J Immunol* 137:3375, 1986
5. Ritz J, Campen TJ, Schmidt RE, Royer HD, Hercend T, Hussey RE, Reinherz EL: Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. *Science* 228:1540, 1985
6. Loughran TP Jr, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteché C, Lum LG, Slichter SJ: Leukemia of large granular lymphocytes: Association of clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia and hemolytic anemia. *Ann Intern Med* 102:169, 1985
7. Loughran TP Jr, Starkebaum G: Large granular lymphocyte leukemia: Report of 38 cases and review of the literature. *Medicine* 66:397, 1987
8. Loughran TP Jr, Starkebaum G, Kidd P, Neiman P: Clonal proliferation of large granular lymphocytes in rheumatoid arthritis. *Arthritis Rheum* (in press)
9. Loughran TP Jr, Draves KE, Starkebaum G, Kidd P, Clark EA: Induction of NK activity in large granular lymphocyte leukemia: Activation with anti-CD3 monoclonal antibody and interleukin 2. *Blood* 69:72, 1987
10. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J Mol Biol* 98:503, 1975
11. Thompson CB, Challoner PB, Neiman PE, Groudine M: Expression of the *c-myc* proto-oncogene during cellular proliferation. *Nature* 319:374, 1986
12. Yanagi Y, Chan A, Chin B, Minden M, Mak TW: Analysis of cDNA clones specific for human T cells and the α and β chains of the T-cell receptor heterodimer from a human T-cell line. *Proc Natl Acad Sci USA* 82:3430, 1985
13. Yoshikao Y, Anatoniou D, Clark SP, Yanagi Y, Sangster R, Van den Elsen P, Cox T, Mak TW: Sequence and expression of transcripts of the human T-cell receptor β -chain genes. *Nature* 312:521, 1984
14. Griesser H, Feller A, Lennert K, Tweedale M, Messner HA, Zalcberg J, Minden MD, Mak TW: The structure of the T cell gamma chain gene in lymphoproliferative disorders and lymphoma cell lines. *Blood* 68:592, 1986
15. Collins SJ, Kubonishi I, Miyoshi I, Groudine M: Altered transcription of the *c-abl* oncogene in K-562 and other chronic myelogenous leukemia cells. *Science* 225:72, 1984
16. Sangster RN, Minowada J, Suciu-Foca N, Minden M, Mak TW: Rearrangement and expression of the α , β , γ chain T cell receptor genes in human thymic leukemia cells and functional T cells. *J Exp Med* 163:1491, 1986
17. Strauss WM, Quertermous T, Seidman JG: Measuring the human T cell receptor γ -chain locus. *Science* 237:1217, 1987
18. Rambaldi A, Pelicci P-G, Allavena P, Knowles DM, Rossini S, Bassan R, Barbui T, Dalla-Favera R, Mantovani A: T cell receptor β chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. *J Exp Med* 162:156, 1985
19. Chan WC, Link S, Mawle A, Check I, Brynes RK, Winton EF: Heterogeneity of large granular lymphocyte proliferations. Delineation of two major subtypes. *Blood* 68:1142, 1986
20. Grillot-Courvalin C, Vinci G, Tsapis A, Dokhelar M-C, Vainchenker W, Brouet J-C. The syndrome of T8 hyperlymphocytosis: Variation in phenotype and cytotoxic activities of granular cells and evaluation of their role in associated neutropenia. *Blood* 69:1204, 1987
21. Waldmann TA, Davis MM, Bongiovanni KF, Korsmeyer SJ: Rearrangements of genes for the antigen receptor on T cells as markers of lineage and clonality in human lymphoid neoplasms. *N Engl J Med* 313:776, 1985
22. Freimark B, Lanier L, Phillips J, Quertermous T, Fox R: Comparison of T cell receptor gene rearrangements in patients with large granular T cell leukemia and Felty's syndrome. *J Immunol* 138:1724, 1987
23. Ikuta K, Hattori M, Wake K, Kano S, Honjo T, Yodoi J, Minato N: Expression and rearrangement of the α , β , and γ chain genes of the T cell receptor in cloned murine large granular lymphocyte lines. No correlation with the cytotoxic spectrum. *J Exp Med* 164:428, 1986
24. Moingeon P, Jitsukawa S, Faure F, Troalen F, Triebel F, Graziani M, Forestier F, Bellet D, Bohuon C, Hercend T: A γ -chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity. *Nature* 325:723, 1987
25. Pelicci P-G, Allavena P, Subar M, Rambaldi A, Pirelli A, Di Bello M, Barbui T, Knowles II DM, Dalla-Favera R, Mantovani A: T Cell Receptor (α , β , γ) Gene Rearrangements and Expression in Normal and Leukemic Large Granular Lymphocytes/Natural Killer Cells. *Blood* 70:1500, 1987